Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.62 |
| ▸ | CA1 | P00915 | 5/20 | 0.62 |
| ▸ | CA2 | P00918 | 5/20 | 0.62 |
| ▸ | CA9 | Q16790 | 5/20 | 0.62 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.61 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.61 |
| ▸ | SUCNR1 | Q9BXA5 | 9/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2025554 | 0.92 | CA12 (0.60) | CA12CA1CA2CA9ITGB3 | |
| SCHEMBL28577195 | 0.92 | CA12 (0.60) | CA12CA1CA2CA9ITGB3 | |
| SCHEMBL7293433 | 0.90 | CA12 (0.61) | CA12CA1CA2CA9ITGB3 | |
| SCHEMBL7493207 | 0.89 | CA12 (0.60) | CA12CA1CA2CA9ITGB3 | |
| SCHEMBL7300004 | 0.87 | ITGB3 (0.64) | CA12CA1CA2CA9ITGB3 | |
| SCHEMBL7352113 | 0.86 | ITGB3 (0.66) | CA12CA1CA2CA9ITGB3 | |
| SCHEMBL25310398 | 0.86 | SUCNR1 (0.49) | CA12CA1CA2CA9ITGB3 | |
| SCHEMBL25310401 | 0.86 | SUCNR1 (0.49) | CA12CA1CA2CA9ITGB3 | |
| SCHEMBL12709532 | 0.83 | CA1 (0.70) | CA12CA1CA2CA9ITGB3 | |
| SCHEMBL8933079 | 0.83 | REN (0.57) | CA12CA1CA2CA9ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0478328-B1 | Novel fibrinogen receptor antagonists | MERCK & CO INC (US) | 1996-01-10 | — | — | EP | disclosed |
| EP-0528586-B1 | Inhibiting osteoclast-mediated bone resorption using aminoalkyl-substituted phenyl derivatives | MERCK & CO INC (US) | 1995-02-22 | — | — | EP | disclosed |
| US-5294616-A | Anticoagulants, inhibition of fibrinogen binding to blood platelets | MERCK & CO., INC. (US) | 1994-03-15 | — | — | US | disclosed |
| US-5217994-A | METHOD OF INHIBITING OSTEOCLAST-MEDIATED BONE RESORPTION BY ADMINISTRATION OF AMINOALKYL-SUBSTITUTED PHENYL DERIVATIVES | MERCK & CO., INC. (US) | 1993-06-08 | — | — | US | disclosed |
| US-5204350-A | Treating osteoporosis | MERCK & CO., INC. (US) | 1993-04-20 | — | — | US | disclosed |
| EP-0528587-A1 | Inhibiting osteoclast-mediated bone resorption using substituted phenyl derivatives | MERCK & CO. INC. (US) | 1993-02-24 | — | — | EP | disclosed |
| EP-0528586-A1 | Inhibiting osteoclast-mediated bone resorption using aminoalkyl-substituted phenyl derivatives | MERCK & CO. INC. (US) | 1993-02-24 | — | — | EP | disclosed |
| EP-0478328-A1 | Novel fibrinogen receptor antagonists | MERCK & CO. INC. (US) | 1992-04-01 | — | — | EP | disclosed |